Life Science Insights 360 Podcasts

Life Science Insights360
  • 0.0 (0)
  • Life Sciences
  • Updated Daily

Welcome to Life Science Insights360, your go-to source for deep conversations with the innovators shaping the future of healthcare, biotech, and life sciences. Hosted by Senthil Karunanith, each episode dives into cutting-edge topics—from translational omics and therapeutic breakthroughs to strategic data insights, quality management, and real-world challenges in pharma, medtech, and diagnostics . Expect dynamic interviews with industry leaders—CEOs, scientists, strategists—who share real-world case studies and forward-thinking visions.

  1. E24 - Transforming Scientific Documents with AI | Levi S. Lian | CEO & Founder, Raycaster

    Apr 6

    E24 - Transforming Scientific Documents with AI | Levi S. Lian | CEO & Founder, Raycaster

    In this episode, we sit down with Levi S. Lian, CEO and Founder of Raycaster, to explore the critical evolution of document intelligence within the enterprise landscape. Drawing from a background that spans Stanford, Harvard Business School, and a deep-rooted family history in medicine, Levi shares his unique perspective on building AI-driven infrastructure that tackles one of the most persistent bottlenecks in modern business: the unstructured and complex document. The conversation centers on the shift from traditional OCR and simple automation toward true document reasoning. We examine why scientific and technical documents pose such a significant challenge for legacy systems and how Raycaster is enabling organizations to move beyond mere data extraction to achieve actionable insights. We take a closer look at the strategic hurdles of enterprise AI adoption, discussing the vital balance between rapid product innovation and the rigorous demands of data security, accuracy, and regulatory compliance. Listeners will gain a masterclass in the future of knowledge work and the ROI of modernizing document-heavy workflows. We discuss Levi’s journey as both a technical founder and an angel investor, offering insights into scaling AI infrastructure, overcoming misconceptions about machine intelligence, and the long-term risks facing industries that remain tethered to manual document processing.

    1 hr
  2. E23 - Building a Therapeutics Platform from the Ground Up | Dr. Stanley Lewis, CEO of A28 Therapeutics

    Mar 23

    E23 - Building a Therapeutics Platform from the Ground Up | Dr. Stanley Lewis, CEO of A28 Therapeutics

    In this episode, we are joined by Dr. Stanley T. Lewis, MD, MPH, Founder and CEO of A28 Therapeutics, to trace his profound transition from physician-scientist to biotech entrepreneur. With a career rooted in translational medicine and clinical development, Dr. Lewis provides an expert perspective on the arduous journey of moving innovation from the laboratory bench to the patient’s bedside. We dive into his mission to redefine precision oncology through Targeted Oncolytic Peptides (TOPs)—a novel modality designed to treat cancer with surgical precision while prioritizing the patient’s quality of life. The conversation explores the strategic and scientific architecture required to build a therapeutics platform from scratch. We examine the lessons learned from Dr. Lewis’s previous success in bringing Trogarzo to market and how those cross-disciplinary insights from virology and infectious diseases are now being applied to solve unmet clinical needs in oncology. We take a closer look at the evolution of A28’s pipeline, discussing how the integration of biomarkers and advanced delivery systems is shaping the next generation of targeted cancer treatments. Listeners will gain a rare look at the human-centered side of biotech leadership. We discuss the complexities of navigating regulatory milestones and financing, the importance of maintaining scientific rigor under the pressure of patient urgency, and why empathy remains the most critical component of medical innovation. Whether you are a scientist, a founder, or a healthcare leader, this episode offers a roadmap for balancing high-stakes operational execution with a steadfast focus on the human impact of medicine.

    28 min
  3. E22 - Advancing the Future of Therapeutics | Ganesh Iyer, CEO & Founder, Opprtna Therapeutics

    Mar 2

    E22 - Advancing the Future of Therapeutics | Ganesh Iyer, CEO & Founder, Opprtna Therapeutics

    In this episode, we sit down with Ganesh Iyer, CEO and Founder of Opprtna Therapeutics and Drug Discovery Partners, to explore the high-stakes world of deep science entrepreneurship. Ganesh shares the personal and professional motivations that led him to tackle some of medicine's most formidable challenges—neurodegeneration and cancer. We delve into the founding vision of Opprtna and its pursuit of a "premium" therapeutics platform that leverages the unique capabilities of aptamers to reach targets once considered undruggable. The conversation provides a technical yet accessible deep dive into aptamer-based modalities, comparing their precision and flexibility to traditional antibodies and small molecules. We examine the specific hurdles of Central Nervous System (CNS) targeting and the innovative delivery strategies required to cross the blood-brain barrier. Ganesh shares his expertise on translating early-stage preclinical discovery into clinical-ready assets, emphasizing the necessity of scientific rigor and strategic target selection in a competitive biotech landscape. Listeners will gain a comprehensive look at the business of drug discovery, from navigating complex funding environments to building multidisciplinary teams that can scale. We discuss the balance between maintaining robust in-house capabilities and leveraging external partnerships to accelerate innovation. Whether you are an aspiring scientist-founder or a seasoned industry leader, this episode offers vital insights into the leadership, culture, and breakthroughs defining the next frontier of precision medicine.

    48 min
  4. E21 - Innovation Infrastructure and Future of Synthetic Biology | Jodi Barrientos CEO, Ribbon Bio

    Feb 23

    E21 - Innovation Infrastructure and Future of Synthetic Biology | Jodi Barrientos CEO, Ribbon Bio

    In this episode, we sit down with Jodi Barrientos, CEO of Ribbon Bio, to explore how innovation infrastructure is shaping the future of synthetic biology—and why scalable DNA manufacturing is critical to unlocking the next generation of biological breakthroughs. Jodi shares her journey from bench scientist to biotech entrepreneur, reflecting on the pivotal moments that inspired her to build a deep-tech company at the intersection of science, engineering, and advanced manufacturing. She discusses the founding vision behind Ribbon Bio and the mission to overcome longstanding limitations in traditional DNA synthesis technologies. At the core of the conversation is the challenge of engineering long, complex, high-fidelity DNA constructs—an essential capability for advancing therapeutics, vaccines, agriculture, and industrial biotechnology. Jodi explains how integrating automation, precision engineering, and computational tools enables a new level of scalability and reliability in synthetic DNA production. By combining advanced manufacturing principles with biological design, Ribbon Bio is building the infrastructure needed to accelerate innovation across the life sciences ecosystem. We also examine the growing role of computational tools and AI in DNA design—how digital modeling and predictive systems can optimize sequence construction, reduce errors, and streamline development cycles. Jodi highlights the commercialization challenges inherent in deep-tech biotech, from capital intensity to long development timelines, and shares leadership lessons learned while building resilient, highly technical teams. Episode Highlights: Ribbon Bio’s approach to redefining synthetic DNA manufacturing Why scalable innovation infrastructure is critical for biotech growth How precision, automation, and computational tools transform bioengineering Insights into leading and scaling a deep-tech company A forward-looking perspective on programmable biology and its impact across industries This episode offers valuable insights for biotech founders, synthetic biology innovators, investors, and scientist-entrepreneurs seeking to understand how infrastructure, scale, and precision will define the future of programmable biology.

    30 min
  5. E20 - Re-inventing Precision Medicine with AI | Jolly Nanda, Founder and CEO, Altheia, Inc

    Feb 9

    E20 - Re-inventing Precision Medicine with AI | Jolly Nanda, Founder and CEO, Altheia, Inc

    In this episode, we sit down with Jolly Nanda, Founder and CEO of Altheia, Inc., to explore how artificial intelligence is transforming precision medicine from a reactive model into one that is predictive, personalized, and proactive. Jolly shares her entrepreneurial journey and the inspiration behind founding Altheia, highlighting the gaps she observed in traditional precision medicine approaches. While precision medicine has made meaningful progress, much of today’s healthcare system still reacts to disease after symptoms appear. Jolly explains how AI-driven insights are changing that paradigm—unlocking deeper understanding from complex patient data, accelerating diagnostics, and enabling earlier, more targeted interventions. At the core of the conversation is the convergence of AI, clinical data, genomics, and digital health. By integrating multi-omics datasets with real-world clinical information, machine learning models can identify subtle patterns and correlations that would otherwise remain hidden. These insights allow for improved disease prediction, earlier detection, and more individualized therapeutic strategies tailored to each patient’s biological profile. We also discuss the practical realities of building and scaling AI solutions in healthcare. From regulatory and interoperability challenges to adoption within clinical and commercial environments, Jolly outlines the importance of balancing innovation with trust, transparency, and governance. Responsible AI—grounded in ethical frameworks and robust validation—is essential to ensuring that predictive technologies truly serve patients and providers. Episode Highlights: How AI is shifting healthcare from reactive treatment to predictive, preventive care The power of data-driven personalization in improving patient outcomes Insights into building and scaling an AI-first precision medicine company The importance of ethical frameworks, transparency, and responsible AI deployment A forward-looking vision for AI-enabled, proactive healthcare innovation This episode offers valuable perspective for healthcare leaders, digital health innovators, biopharma executives, and technologists seeking to understand how AI is reshaping precision medicine—and how predictive intelligence will define the next era of healthcare.

    37 min
  6. E19 - Future of Innovation and Ecosystem | James Zanewicz CEO, Connect

    Jan 19

    E19 - Future of Innovation and Ecosystem | James Zanewicz CEO, Connect

    In this episode, we explore how San Diego is evolving as a global innovation hub—and what it will take to shape its next chapter at the convergence of AI, DefenseTech, and Life Sciences. Long recognized for its strengths in biotech and research institutions, San Diego is now entering a new phase defined by cross-sector collaboration and technological convergence. We examine what differentiates the region from other emerging innovation hubs: a unique blend of research excellence, defense infrastructure, entrepreneurial culture, and global connectivity. The conversation dives into how ecosystems can effectively support both early-stage startups and established industry leaders. As AI reshapes medtech, biotech, and adjacent sectors, the crossover between technology and life sciences is accelerating—unlocking new models of product development, commercialization, and impact. We discuss how founders can leverage this convergence to build more resilient and scalable companies. We also address the realities entrepreneurs face today: evolving venture funding dynamics, heightened competition for capital, talent acquisition challenges, and the complexity of global expansion. Founders must move beyond pitching ideas to building investable, execution-ready organizations. Capital strategy now demands clarity, differentiation, and disciplined storytelling that resonates with both investors and customers. A key theme of the episode is “StoryMaking”—the idea that momentum-driven narratives are more powerful than static origin stories. Translating deep science and complex technology into compelling, forward-looking messages is essential for attracting capital, talent, and partnerships. In a crowded global market, narrative clarity can be as important as technical excellence. We also reflect on leadership within historic organizations navigating reinvention—how to balance legacy and culture with transformation and growth. Mentorship, long-term perspective, and principled decision-making play critical roles in shaping sustainable innovation ecosystems. Episode Highlights: A strategic look at San Diego’s next phase as a global innovation hub Insights into the convergence of AI, DefenseTech, and Life Sciences Practical guidance on capital strategy and investor readiness A fresh perspective on StoryMaking as a driver of ecosystem momentum Actionable advice for global scaling while maintaining focus and resilience Leadership reflections on legacy, reinvention, and mentorship Bold predictions on the future of global innovation ecosystems This episode is essential listening for founders, investors, operators, and ecosystem builders working to shape not only San Diego’s future—but the broader trajectory of global innovation in the decade ahead.

    32 min
  7. E18 - Re-Imagining Clinical Development Strategy|Suzanne Vyvoda Founder,CEO of Concordia BioStrategies

    Jan 5

    E18 - Re-Imagining Clinical Development Strategy|Suzanne Vyvoda Founder,CEO of Concordia BioStrategies

    In this episode, we sit down with Suzanne Vyvoda, Founder and CEO of Concordia BioStrategies, to explore how strategic leadership, operational rigor, and collaborative execution form the foundation of successful biotech companies. Suzanne shares her journey to becoming a founder, CEO, and trusted strategic partner to emerging biotech organizations. She reflects on the philosophy behind Concordia BioStrategies—rooted in alignment, collaboration, and shared purpose—and why early-stage companies must build strong operational frameworks long before a clinical trial begins. A central theme of the conversation is the evolving role of the Fractional C-Suite leader. Suzanne explains how this model provides growing biotechs with access to senior-level expertise without the overhead of full-time executive hires. In capital-constrained environments, fractional leadership allows companies to move strategically and efficiently—bringing experienced guidance during critical inflection points while preserving runway. We dive into why operational excellence must start at the earliest stages of company formation. Too often, companies focus heavily on scientific progress while underestimating the infrastructure required to transition into clinical development. Suzanne outlines common operational pitfalls—from misaligned vendors and unclear governance structures to gaps in quality and compliance—and shares practical frameworks for aligning strategy, operations, and execution. The conversation also emphasizes balance: how companies can move quickly without sacrificing quality, regulatory discipline, or scientific integrity. Early operational decisions, Suzanne notes, directly influence scalability, investor confidence, and ultimately patient impact. Creating alignment between founders, internal teams, CROs, and external partners is not optional—it is essential. Episode Highlights: A founder story grounded in collaboration, clarity, and execution A clear explanation of the Fractional C-Suite model and its strategic value Practical guidance on operational readiness before entering the clinic Real-world insights into avoiding costly clinical-stage missteps A thoughtful framework for balancing speed, quality, and long-term value creation This episode is essential listening for biotech founders, emerging executives, and investors seeking to understand how disciplined operations, strategic alignment, and experienced leadership can accelerate the journey from discovery to the clinic—while building resilient companies designed for sustainable growth.

    52 min
  8. E17 - Driving Diversity in Clinical Research | Golda Naana Boakye CEO Naantu

    12/29/2025

    E17 - Driving Diversity in Clinical Research | Golda Naana Boakye CEO Naantu

    Join us for a powerful and timely episode featuring Golda Naana Boakye, CEO of Naantu, as we examine the urgent need to advance diversity, equity, and inclusion in clinical research. In this compelling conversation, Golda shares why representative clinical trials are not only a matter of social responsibility, but a scientific and clinical imperative essential to improving outcomes for all patients. We explore the systemic and structural barriers that continue to limit participation from underrepresented communities, from historical mistrust and access challenges to trial design limitations that fail to reflect real-world populations. Golda discusses the importance of rebuilding trust through transparency, meaningful community engagement, and culturally competent communication—shifting clinical research from a transactional model to a patient-centered partnership. The conversation also highlights how innovative, technology-enabled approaches are helping to remove logistical barriers, expand access, and enhance the participant experience. From decentralized trial models to data-driven outreach strategies, we examine how sponsors and CROs can move beyond intention and toward measurable action in equity-driven research. Episode Highlights: A deep dive into why diversity in clinical trials strengthens scientific validity and patient outcomes Key structural barriers preventing broader participation—and how to address them The critical role of trust, transparency, and community engagement in recruitment How digital tools and decentralized models can improve accessibility and inclusivity Golda’s leadership journey and the mission driving Naantu Practical strategies for sponsors and research organizations to build more representative trials A forward-looking vision for patient-centric, equitable clinical research Whether you're a biopharma executive, clinical researcher, sponsor, or healthcare innovator, this episode offers strategic clarity and actionable insights on building trials that truly reflect the populations they aim to serve. Discover how inclusive research design is shaping the future of medicine—and why equity must be embedded at the core of scientific progress.

    51 min
See All (24)

About

Welcome to Life Science Insights360, your go-to source for deep conversations with the innovators shaping the future of healthcare, biotech, and life sciences. Hosted by Senthil Karunanith, each episode dives into cutting-edge topics—from translational omics and therapeutic breakthroughs to strategic data insights, quality management, and real-world challenges in pharma, medtech, and diagnostics . Expect dynamic interviews with industry leaders—CEOs, scientists, strategists—who share real-world case studies and forward-thinking visions.

Information